Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective : pan European patient survey by Canonica, Walter G. et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=icmo20
Current Medical Research and Opinion
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/icmo20
Burden of allergic rhinitis and impact of MP-
AzeFlu from the patient perspective: pan European
patient survey
G. Walter Canonica, Ludger Klimek, Sarah Acaster, Ralph Dollner, Ranbir
Kaulsay, Siu Hing Lo, David B. Price, Glenis K. Scadding, Erkka Valovirta &
Petra Zieglmayer
To cite this article: G. Walter Canonica, Ludger Klimek, Sarah Acaster, Ralph Dollner, Ranbir
Kaulsay, Siu Hing Lo, David B. Price, Glenis K. Scadding, Erkka Valovirta & Petra Zieglmayer
(2021) Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan
European patient survey, Current Medical Research and Opinion, 37:7, 1259-1272, DOI:
10.1080/03007995.2021.1911973
To link to this article:  https://doi.org/10.1080/03007995.2021.1911973
© 2021 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
View supplementary material 
Published online: 20 Apr 2021. Submit your article to this journal 
Article views: 584 View related articles 
View Crossmark data
ORIGINAL ARTICLE
Burden of allergic rhinitis and impact of MP-AzeFlu from the patient
perspective: pan European patient survey
G. Walter Canonicaa,b, Ludger Klimekc, Sarah Acasterd, Ralph Dollnere, Ranbir Kaulsayf, Siu Hing Lod,
David B. Priceg,h,i , Glenis K. Scaddingj, Erkka Valovirtak and Petra Zieglmayerl,m
aPersonalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Milan, Italy; bDepartment of Biomedical
Sciences, Humanitas University, Milan, Italy; cZentrum f€ur Rhinologie und Allergologie, Wiesbaden, Germany; dAcaster Lloyd Consulting Ltd,
London, UK; eDivision of Head, Neck and Reconstructive Surgery, Department of Otorhinolaryngology, Oslo University Hospital
Rikshospitalet, Oslo, Norway; fBeacon Hospital and Bon Secours Hospital, Dublin, Ireland; gOptimum Patient Care, Cambridge, UK;
hObservational and Pragmatic Research Institute, Singapore, Singapore; iDivision of Applied Health Sciences, Centre of Academic Primary
Care, University of Aberdeen, Aberdeen, UK; jRoyal National Throat, Nose and Ear Hospital, London, UK; kDepartment of Lung Diseases and
Clinical Immunology, University of Turku and Terveystalo Allergy Clinic, Turku, Finland; lPower Project GmbH, Vienna Challenge Chamber,
Vienna, Austria; mKarl Landsteiner University, Krems, Austria
ABSTRACT
Objective: The aims of this survey were to (1) assess the burden of allergic rhinitis (AR) from the
patient perspective, (2) investigate MP-AzeFlu use in real life and its impact on patients’ lives and (3)
explore factors associated with treatment satisfaction.
Methods: A cross-sectional, quantitative, online, questionnaire-based survey was conducted in seven
European countries (March–June 2019). Questions explored AR burden and treatment satisfaction.
Satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication 9-item (TSQM-
9; max score ¼ 100). Participants (aged 18 years) had a doctor/healthcare provider confirmed AR
diagnosis and used MP-AzeFlu within the last year.
Results: Pre-MP-AzeFlu treatment, participants (n¼ 1004) reported an average of 3.3 (SD:3.5) doctor
visits/year, 8.1 (SD:11.0) days/year absenteeism and 15.8 (SD:18.9) days/year presenteeism due to AR.
Only 48% of participants used MP-AzeFlu twice/day as recommended. Post-MP-AzeFlu 57% of partici-
pants reported better QoL, 47% reported fewer doctor visits and 52% discontinued polypharmacy.
Absenteeism and presenteeism were reduced by 2.5 (SD 10.0) and 7.3 (SD:16.0) days/year, respectively.
70% of participants were more/much more satisfied with MP-AzeFlu versus previous AR treatment(s),
and 70% were satisfied/extremely satisfied with its ability to prevent/treat AR, relieve symptoms and
with its onset of action. Mean global, effectiveness and convenience TSQM-9 scores were 70.0
(SD:19.8), 68.3 (SD:21.6) and 72.7 (SD:20.4), respectively. Treatment satisfaction and effectiveness were
significantly improved when MP-AzeFlu was taken as recommended.
Conclusions: The impact of AR on patients’ lives remains high. Real-life use of MP-AzeFlu reduces that
impact and is associated with a high level of effectiveness, convenience and global satisfaction.
Abbreviations: AR: allergic rhinitis; ARIA: allergic rhinitis and its impact on asthma; EAACI: European
Academy of Allergy and Clinical Immunology; EUFOREA: European Forum for Research and Education
in Allergy and Airway diseases; HCP: healthcare provider; HCRU: healthcare resource utilisation; HDM:
house dust mite; INS: intranasal corticosteroid; NO: Norway; PAR: perennial allergic rhinitis; QoL: quality
of life; RCT: randomized controlled trial; SAR: seasonal allergic rhinitis; SD: standard deviation; TSQM-9:
Treatment Satisfaction Questionnaire for Medication 9-item
ARTICLE HISTORY
Received 2 December 2020
Revised 21 March 2021







Allergic rhinitis (AR) is frequently under-diagnosed, self-man-
aged and sub-optimally treated1–3. Poly-pharmacy is com-
mon, adherence to treatment regimens is poor and,
unsurprisingly nasal and ocular symptom burden remains
high1,4,5. These symptoms impair daily activities6, negatively
impact patient quality of life (QoL)7,8 and reduce
productivity, both at work and school1,5,9. AR is rarely found
in isolation; 20–60% of those with AR also have clinical
asthma10,11, with the presence of symptomatic AR associated
with worsening asthma control12. AR is a costly disease to
manage (mostly due to indirect costs), but direct costs are
not insubstantial estimated at e210.30/patient per year in a
recent Swedish survey13. However, most patients are not sat-
isfied with their AR treatment5,14.
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Knowledge of patient preferences and expectations from
their AR treatment helps to explain why so many remain dis-
satisfied. In terms of treatment expectations, these are often
high; one survey conducted in Belgium found that four out
of every 10 patients attending a specialist for their AR
expected to be cured by the prescribed treatment15. In terms
of preference, AR patients want treatments that are rapidly
acting, provide complete symptom relief, target both nasal
and ocular symptoms and have a long duration of
action1,16–18. Preference for some of these attributes has
been quantified in the UK; for example, AR patients are over
6 times more likely to prefer an AR treatment that provides
complete symptom relief versus mild symptom relief (all
other attributes being equal) and are willing to pay £0.98 for
each hour of onset faster than 8 h, or £43.81 for a treatment
which provides complete relief versus mild symptom relief16.
There has, therefore, been a shift towards a more patient-
centred approach to AR management, involving patients in
decision making, recognizing they are individuals with associ-
ated values and preferences19,20. The most up to date AR
treatment guidelines and algorithms support this patient-
centered approach21,22. The Allergic Rhinitis and its Impact
on Asthma (ARIA) next generation guidelines (2020) encour-
age healthcare providers (HCPs) to consider both patient
preference and AR management behavior in real-life (e.g.
poor adherence and treatment switching)21. Similarly, the
European Forum for Research and Education in Allergy and
Airway diseases (EUFOREA) encourage patient participation
in the decision-making process and in goal setting, and
emphasize the need to match therapy to these goals and to
patient preference23. Patient-reported outcome measures are,
therefore, now regarded as at least as important as the trad-
itional objective measures of disease as they provide unique
and complementary information24. Indeed, higher patient
treatment satisfaction is a significant predictor of more
favourable clinical outcomes25.
The aims of this survey were to (i) assess the burden of
AR from the patient perspective, (ii) investigate how patients
use MP-AzeFlu (Dymista, Mylan, USA) in real life, (iii) evaluate
the impact of MP-AzeFlu on patients’ lives and (iv) explore
factors associated with treatment satisfaction.
Methods
Survey design
This was a cross-sectional, quantitative, online, questionnaire-
based survey to assess patient satisfaction with MP-AzeFlu
treatment. MP-AzeFlu comprises an intranasal corticosteroid
(INS; fluticasone propionate) and an intranasal antihistamine
(azelastine) in an advanced formulation, delivered as a single
spray and is indicated for the treatment of moderate/severe
AR26. The survey was conducted in seven European countries
(Austria, Finland, Germany, Ireland, Italy, Norway and the UK)
from the end of March to April 2019 (Austria, Germany, Italy)
and from mid-April to June 2019 (Finland, Ireland, Norway
and the UK). The survey protocol was reviewed and received
exempt status determination by an independent review
board (Western Institutional Review Board) prior to partici-
pant recruitment (13 December 2019).
Recruitment
Potential participants were recruited via a healthcare agency
(Global Perspectives, UK & Spain) who used panel and
bespoke ad-hoc recruitment from HCP referral, relevant char-
ities, patient associations/communities and social media.
These patients were invited to complete the survey via e-
mail and were provided with the survey address (web link)
and unique identifier, which they could use to access the
online survey. The aim was to recruit 1000 AR participants;
n¼ 200 from Germany, Italy and the UK and n¼ 100 from
Austria, Finland, Ireland and Norway. Once target sample
sizes were reached, recruitment was closed.
Patients
Those following the link were screened in accordance with
the inclusion/exclusion criteria (online supplement: appendix
A). Those residing in one of the aforementioned countries,
aged 18 years, with a doctor/HCP confirmed diagnosis of
AR, and who had started using MP-AzeFlu within the last
7 years, had used it to treat AR symptoms within the last
12months and were willing/able to provide informed con-
sent were included. If eligible, patients were next directed to
consent information and asked to provide informed consent
via an online consent form (online supplement; appendices B
and C). All subjects were free to withdraw from participation
in this survey at any time, and for any reason. Willing and eli-
gible participants then completed the online survey (online
supplement; appendix D).
Survey
The survey was developed by Acaster Lloyd Consulting in
collaboration with Mylan. It included 4 domains: (i) your
health, (ii) your treatment for AR, (iii) satisfaction with MP-
AzeFlu and (iv) about you. For non-English speaking coun-
tries, the survey and other study materials were translated
into the local language. The “your health” section of the sur-
vey included questions on age at diagnosis, type of AR, trig-
gers, symptoms, impact on QoL, as well as impact on daily
living and on co-morbid asthma. The “your treatment for AR”
section captured information on previous AR treatment,
healthcare resource utilization (HCRU), absenteeism, present-
eeism, reasons for using MP-AzeFlu, treatment pattern (e.g.
frequency, polypharmacy), and expectations from treatment.
Response options for items concerning allergy triggers and
type of treatments were adapted to cover all relevant aller-
gens and treatments in each country. Information on
employment status and highest level of education achieved
was captured in the “about you” section of the survey.
Depending on the nature of the question, participants either
selected a provided option or options (e.g. AR treatment(s)
used), inputted information (e.g. number of days absent/year
due to AR), or expressed their opinion using a 5- or 7-point
1260 G. W. CANONICA ET AL.
Likert scale (e.g. the Treatment Satisfaction Questionnaire for
Medication 9-item (TSQM-9) rated overall satisfaction with
MP-AzeFlu from 1: extremely dissatisfied to 7 extremely satis-
fied). The full list of questions and provided response options
are provided in the online supplement (appendix D).
Satisfaction with MP-AzeFlu
Satisfaction with MP-AzeFlu was assessed using the TSQM-
927 plus additional questions. The abbreviated form is
divided into three domains: effectiveness, convenience and
global satisfaction, each scored from 0 to 100. Instructions to
patients were modified for the current survey to reflect the
non-interventional nature of the survey and online adminis-
tration. All modifications were approved by the scale’s
licence holder.
Statistics
All survey items were summarized using descriptive statistics.
Change scores in QoL between on and off treatment were
calculated. For healthcare visits, productivity and use of other
treatments pre- and post-MP-AzeFlu change scores were cal-
culated. Changes were categorised as “worse/more impact/
more healthcare visits,” “no change” or “improved/less
impact/fewer healthcare visits.” Data were also described by
country of residence. Country differences in participant
socio-demographics and MP-AzeFlu treatment satisfaction
measures were tested using simple regression models or chi-
square tests as appropriate.
Post-hoc analyses were also conducted to compare TSQM
global satisfaction, effectiveness and convenience scores for
patients on MP-AzeFlu only (n¼ 708) vs MP-AzeFlu plus 1
other AR treatment (n¼ 296) and for patients with AR only
(n¼ 513) and those with AR and asthma (n¼ 470). All statis-
tical tests were two-sided and p-values of < .05 were consid-




A total of 1004MP-AzeFlu users completed the online survey
(Austria: n¼ 100, Finland: n¼ 100, Germany: n¼ 202; Ireland:
n¼ 101; Italy: n¼ 201; Norway: n¼ 100; UK: n¼ 200).
Socio-demographic profile of MP-AzeFlu users
(Table 1)
Participants had a mean age of 37.7 (standard deviation (SD):
12.0) years, were gender balanced, with the majority being
employed full time (67%) and educated to degree level or
higher (67%). Age, employment status and educational level
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Clinical characteristics (Table 2)
The average age of AR diagnosis was 24.3 (13.9) years. Most
participants considered that they had either seasonal AR
(SAR; 66%) or SARþperennial AR (PAR; 30%). Grass and birch
pollen were the most common triggers (70% and 53%,
respectively), but the ratio of grass to birch pollen allergy
varied by country. House dust mite (HDM) allergy was
reported by 46% of participants; lowest in Finland (21%) and
highest in Italy (60%), but Ireland, Norway and the UK had a
HDM trigger prevalence of 50%. The most common symp-
toms experienced by participants were those usually
assessed in AR trials (i.e. nasal congestion, itching, rhinor-
rhoea and sneezing and ocular itching, watering and red-
ness). But other symptoms (usually not assessed in trials)
were also reported by 20% of patients including itchy
mouth, sinus pressure, cough, sore throat, headache,
and wheezing.
Burden of AR when not treated (Table 3)
Quality of life
Almost half of all participants (n¼ 471; 47%) reported poor
or fair QoL when not on treatment, ranging from 31% in the
UK to 62% in Finland. Of these patients, the most negatively
affected areas of life were daily activities (75%), followed by
sleep (52%), leisure activities (51%), social activities (42%)
and emotional well-being (39%). Daily activities were rated
as the most negatively impacted area of life by most partici-
pants in all countries, with the exception of Norway where
sleep was considered by most participants to have the great-
est impact.
Symptoms
Nasal congestion was reported overall as having the greatest
impact on participants’ lives when not on AR treatment
(18%), followed by runny nose and itchy eyes (16% each)
and then sneezing (12%). Nasal congestion also had the
greatest impact on participants from Austria, Finland,
Germany and Italy. However, for Ireland it was runny nose
and for participants from Norway and the UK it was
itchy eyes.
Healthcare resource utilization
When not on MP-AzeFlu treatment participants reported an
average of 3.3 (SD 3.5) doctor visits/year, 1.7 (SD 3.1) allergy
specialist visits/year, 1.2 (SD 2.5) nurse visits/year and 4.2 (SD
5.6) pharmacist visits/year due to AR. Poly-pharmacy was
common, with 48% of participants reporting use of 2 or
more AR treatments prior to MP-AzeFlu (Austria: 46%;
Finland: 47%; Germany: 49%; Ireland: 48%; Italy: 48%;
Norway: 56%; UK: 44%).
Absenteeism and presenteeism
When not on MP-AzeFlu treatment, participants reported an
average of 8.1 (SD 11.0) days missed from work and 15.8 (SD
18.9) days when productivity was negatively impacted due
to AR. Overall, 59% of participants considered that their
productivity was negatively impacted by 50% due to
their AR.
Impact of AR on asthma (Table 2)
Forty-seven percent of participants also reported having co-
morbid asthma. Among these patients, almost two-thirds of
them (63%) stated that they changed their asthma treatment
when last experiencing AR symptoms; 49% reporting an
increase in reliever and 30% an increase in pre-
venter medication.
Pattern of MP-AzeFlu use in real life
On average, participants began using MP-AzeFlu 2.6 (SD 1.5)
years ago. The majority (57%) reported using it in the past
week; with 27%, 10% and 6% of participants confirming use
in the last 1, 3 and 12months, respectively (S-Table 1). When
experiencing symptoms, 36% of participants said they used
MP-AzeFlu every day and 64% used it intermittently.
Germany had the highest prevalence of intermittent users
(74%) and Finland, the least (49%) (S-Table 1). In terms of
dosing, 48% of participants said they used MP-AzeFlu twice
a day (as recommended) (Figure 1). Half of participants
(50%) reported initiating MP-AzeFlu as soon as symptoms
started, and 20% within 1–2 days of symptom start. The
majority of participants either used MP-AzeFlu every day
they expected symptoms (47%) or on days they experienced
symptoms (45%) (S-Table 1).
Reasons for using MP-AzeFlu and perceived benefits and
improvements
The most common reasons given for starting MP-AzeFlu
were that previous treatment did not relieve nasal symptoms
(30% of participants), did not relieve ocular symptoms (26%),
did not work at all (25%), did not work quickly enough
(25%), did not last long enough (25%), and/or did not relieve
other symptoms (20%) (S-Table-2). Participants reported con-
tinuing to use MP-AzeFlu due to its effect on nasal (54%)
and ocular symptoms (44%), and the perception of a more
rapid onset (36%) and longer duration of action (20%) com-
pared to other AR treatments (S-Table-2). Most patients
expected MP-AzeFlu to start working within 15 mins (33%)
or 30 mins (32%) and to feel a maximum response within 1 h
(29%), a few hours (29%) or within a day (20%) (S-Table-2).
Impact of MP-AzeFlu
Quality of life
Overall, only 54% of patients reported good to excellent QoL
when experiencing AR symptoms prior to MP-AzeFlu use, ris-
ing to 91% of patients when treated with MP-AzeFlu (Table
3; Figure 2A). A similar pattern was noted in each country (S-
Table 3). The average change in QoL between off and on
MP-AzeFlu was 0.9 (SD 1.3) on a scale from 1 (poor) to 5
(excellent), corresponding to a 35% improvement in QoL




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1264 G. W. CANONICA ET AL.
when on MP-AzeFlu compared with off treatment (S-Table 4).
Overall, 57% of participants reported better QoL on MP-
AzeFlu, 32% reported no change and 11% reported worse
QoL (Figure 2B).
Healthcare resource utilization
Overall, MP-AzeFlu use was associated with 0.9 (SD 2.8)
fewer doctor visits and 1.6 (SD 4.1) fewer pharmacist vis-
its/year, a 27% and 38% reduction, respectively. Survey
participants from each country reported a reduction in the
number of doctor and pharmacist visits on MP-AzeFlu (S-
Table-4). 47% of participants reported fewer doctor visits
(Figure 3A), and 46% reported fewer pharmacist visits/year
on MP-AzeFlu (Figure 3B). Using MP-AzeFlu was associated
with decreased use of other AR treatments. Post MP-
AzeFlu use, 29% of participants reported poly-pharmacy
use (vs 48% pre-treatment). Among those who reported
polypharmacy use pre-MP-AzeFlu, 52% of participants
reported discontinuation of polypharmacy since using
MP-AzeFlu.
Absenteeism and presenteeism
Compared to off treatment, participants treated with MP-
AzeFlu reported a reduction in absenteeism of 2.5 (SD 10.0)
days/year and a reduction in presenteeism of 7.3 (SD 16.0)
days/year, a 31% and 46% reduction, respectively. A similar
pattern was observed for each country (S-Table 4). When
treated with MP-AzeFlu, 46% of participants reported fewer
days absent from work due to AR, (Figure 4A). 57% reported
fewer days with reduced productivity (Figure 4B), and 51%




70% of participants were more or much more satisfied with
MP-AzeFlu compared to their previous AR treatment (Figure
5A). Previous AR treatments reported included: oral anti-his-
tamines (51%), intranasal anti-histamines (33%), sodium
cromoglycate (17%), leukotriene receptor antagonist (10%),
INS (14%), eye drops (38%) and immunotherapy (7%), with
48% of participants stating that they used 2 treatments.
Some inter-country difference in relative satisfaction rating
was noted among countries, ranging from 63% of
Figure 1. Participant reported daily frequency of MP-AzeFlu use, overall
(n¼ 1004) and by country. Abbreviations. AT, Austria; DE, Germany; FI, Finland;
IE, Ireland; IT, Italy; NO, Norway; UK, United Kingdom.
Figure 2. Participant reported (A) quality of life and (B) change in quality of
life before and after treatment with MP-AzeFlu, overall (n¼ 1004) and by coun-
try. Abbreviations. AT, Austria; DE, Germany; FI, Finland; IE, Ireland; IT, Italy; NO,
Norway; UK, United Kingdom.
Figure 3. % of participants who reported more, fewer or no change in the
number of (A) doctor and (B) pharmacist visits since using MP-AzeFlu, overall
(n¼ 1004) and by country. Abbreviations. AT, Austria; DE, Germany; FI, Finland;
IE, Ireland; IT, Italy; NO, Norway; UK, United Kingdom.
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participants in Norway (who were more or much more satis-
fied with MP-AzeFlu) to 78% in Italy (Figure 5B). Satisfaction
rating was also dependent on MP-AzeFlu usage pattern.
Significantly (p< .001) more participants (76%) were more or
much more satisfied with MP-AzeFlu than their previous AR
treatment when MP-AzeFlu was used every day symptoms
were expected, compared to 66% of participants who used it
only on symptom days (Figure 5A).
TSQM-9
The mean TSQM Global satisfaction score with MP-AzeFlu
was 70.0 (SD 19.8) (Figure 5C) and was significantly (p< .01)
different between countries, ranging from 64.0 in Norway to
approximately 72 in Ireland, Italy and the UK. Overall, 93% of
participants reported feeling somewhat to extremely confi-
dent of the benefits of MP-AzeFlu, 92% were somewhat to
extremely certain that the benefits outweighed the risks and
75% stated that they were satisfied to extremely satisfied
with MP-AzeFlu (Table 4).
The average TSQM-9 effectiveness score with MP-AzeFlu
was 68.3/100.0 (SD 21.6) (Figure 5C) and was significantly
(p< .01) different between countries, ranging from 63.4 in
Norway to 72.9 in the UK. More than or equal to 70% of par-
ticipants reported that they were satisfied to extremely satis-
fied with the ability of MP-AzeFlu to prevent or to treat their
AR, with the way MP-AzeFlu relieved symptoms and with its
onset of action (Table 4).
The average TSQM-9 convenience score for MP-AzeFlu
was 72.7/100.0 (SD 20.4) (Figure 5C). Overall, 74% of partici-
pants reported that MP-AzeFlu was easy to extremely easy to
use and 75% considered it was convenient to extremely con-
venient to take it as instructed (Table 4).
Figure 4. % of participants who reported more, fewer or no change in (A)
number of days off work, (B) number of days with productivity impacted by AR
and (C) productivity impact since using MP-AzeFlu, overall (n¼ 891) and by
country. Abbreviations. AT, Austria; DE, Germany; FI, Finland; IE, Ireland; IT, Italy;
NO, Norway; UK, United Kingdom.
Figure 5. Participant satisfaction with MP-AzeFlu compared to previous AR
treatment (A) for all participants and by treatment pattern (B) by country, (C)
measured using the TSQM-9 (all participants and by treatment pattern) and (D)
measured using the TSQM-9 according to dosing schedule (once daily: n¼ 228;
twice daily: n¼ 481; 3 times/day: n¼ 292. Abbreviations. AT, Austria; DE,
Germany; FI, Finland; IE, Ireland; IT, Italy; NO, Norway; TSQM-9, Treatment
Satisfaction Questionnaire for Medication-9 item; UK, United Kingdom.p< .001; †p< .01.
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TSQM-9- assessed satisfaction (global, effectiveness and
convenience domains) were significantly influenced by MP-
AzeFlu pattern of use, showing significant (p .01) improve-
ment when MP-AzeFlu was used every day symptoms were
expected versus when used only when symptomatic (Figure
5C). TSQM-9-assessed satisfaction (all domains) was also sig-
nificantly impacted by MP-AzeFlu dosing-frequency (Figure
5D). Using MP-AzeFlu less often than recommended was
associated with a 3.9-point decrease in TSQM-global score
(p< .05) and a 4.9-point decrease in TSQM-effectiveness
score (p< .01). Using MP-AzeFlu more often than twice a day
was also associated with a reduction in satisfaction; a
decrease of 3.7 (p< .05), 5.7 (p< .001) and 5.1 (p< .01)
points in global, effectiveness and convenience scores,
respectively (Figure 5D).
Post-hoc analyses
No significant (p¼ .274) difference in mean TSQM Global sat-
isfaction score was noted for patients on MP-AzeFlu alone
(70.4; SD 19.5) versus those on MP-AzeFlu plus 1 other AR
treatment (68.9; SD 20.4) (S-Table 5). Similar TSQM effective-
ness and convenience scores were also reported for those on
MP-AzeFlu alone or on MP-AzeFlu plus other AR treatment(s).
Although both patients with AR only and those with AR and
asthma co-morbidity reported high TSQM global, effective-
ness and convenience scores, those with AR only had signifi-
cantly greater scores compared to those with AR and asthma
(S-Table 5).
Discussion
There is an increasing trend to use real-world data to inform
clinical practice in recognition of the value of the patient
perspective and the need for a patient-centered approach to
AR management. According to ARIA, guidelines are not suffi-
ciently followed because they are not close enough to
patients’ needs and probably do not reflect real life21.
Additionally, the European Academy of Allergy & Clinical
Immunology (EAACI) has called on EU policy makers for pan-
European awareness campaigns to drive recognition of the
burden of allergic disease28. Our pan-European survey
answers those calls to action, seeking to better understand
the real-life AR disease and treatment landscapes, examine
the symptomatic and economic burdens AR places on
patients’ lives, and discover how patients really use their AR
treatment in real-life. We have also highlighted important
gaps in patient knowledge about AR. For example, although
only 34% of participants considered they had PAR or a PAR-
component to their AR, almost half of them reported a HDM
allergy. This means that PAR may be routinely under-recog-
nized in real-life and consequently under-treated. These
findings may be explained, in part, by the seasonality of
HDM-allergy (with symptoms peaking in Spring and
Autumn), which may be confused as SAR29. Indeed, this is
the primary reason why ARIA proposed classifying AR accord-
ing to duration of symptoms (i.e. intermittent/persistent)
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AzeFlu (currently the most effective symptomatic AR treat-
ment)21,30,31 is assessed using outcomes which are relevant
to patients, HCPs, and payers, including QoL, HCRU, absen-
teeism and productivity impact. This survey is the first to
measure satisfaction with MP-AzeFlu using a validated ques-
tionnaire (TSQM-9) and shows an indirect link between satis-
faction and patient reported outcomes.
With more than 150 million EU citizens suffering from
chronic allergic disease, EAACI recognizes the burden of AR
on both sufferers and healthcare economies28. Our survey
quantifies this burden and highlights the debilitating effect
AR has on patients’ lives including the negative impact of
symptoms (notably nasal congestion, rhinorrhoea and itchy
eyes) on patient QoL, daily activities and sleep. The eco-
nomic consequences of that impact are also evident from
the high HCRU (e.g. 3.3 doctor visits/year for AR and a poly-
pharmacy rate (pre-MP-AzeFlu) of 48%), absenteeism
(8.1 days/year) and presenteeism (15.8 days/year) rates
reported, most likely reflecting the severity of symptoms of
those who received MP-AzeFlu. The high total cost of AR has
previously been estimated at e1.3 billion annually in Sweden
(for 9.5 million inhabitants), rising to e55–151 billion/annum
in avoidable indirect costs due to failure to treat allergy
properly in the EU13,32. Other AR surveys have reported a
similarly high burden of AR1,5,6,8,29,33–35. In the UK, AR
patients with moderate severe disease continued to experi-
ence significant nasal and ocular symptoms on treatment
(even though 70.5% of them were on 2AR therapies), vis-
ited their GP 1.61 times/year (due to dissatisfaction in one-
third of cases) and were absent form work/school due to AR
on 4.1 days/year1. Another observational study conducted in
France, Italy and Spain found that 87% of patients with self-
reported AR had attended an allergist in the last year29.
Others reported that AR symptoms were severe enough to
interfere with daily activities, reduce sleep quality, and nega-
tively impact emotional well-being6. In agreement with our
findings, the presence of AR symptoms (or failure to take AR
medication) was associated with a worsening of asthma con-
trol in co-morbid patients, with severe rhinitis symptoms
affecting asthma control to the same degree as smoking1,12.
After allergen avoidance and saline douching, pharmaco-
therapy remains at the forefront of AR management to com-
bat symptoms and their effects on patients’ lives.
International management guidelines provide treatment rec-
ommendations based on the best available evidence23,36,37.
Traditionally this evidence has come from randomized con-
trolled trials (RCTs), which assess the effect of pharmaco-
therapies under optimal conditions (e.g. good adherence and
technique)38. However, in real life, patients’ treatment behav-
iour can be far from optimal, a fact which is confirmed in
our survey which showed a mis-alignment between guide-
line-directed treatment recommendations and every day
treatment patterns. Participants reported using MP-AzeFlu in
a way which is neither indicated nor studied in RCTs with
respect to both daily usage and daily dosage; 64% of partici-
pants reported using MP-AzeFlu intermittently when experi-
encing symptoms, and 52% did not take it twice daily as
recommended, and thus may not have derived full benefit
from MP-AzeFlu. An intermittent pattern of use may be due
to the fact that most patients suffer from several episodes of
short-term AR symptoms and so rarely take their medication
continuously for 14 days1. The recent introduction of m-
health tools (e.g. patient apps to monitor symptoms and dis-
ease control) to AR management protocols has also shown a
discordance between treatment recommendation and
patient behaviour in real life. For example, a recent study
using the Mask-air app found that 69% of AR patients were
non adherent to medications4. Using the same app it was
found that patients stop and start treatment, frequently
switch treatments and increase the number of AR
medications when they are unwell39,40. However, in the cur-
rent survey participants showed a high degree of loyalty to
MP-AzeFlu, with an average duration of use of 2.57 years.
Better AR control may be achieved by listening to
patients, taking account of how they actually manage their
AR and understanding the reason(s) for their treatment
choices; this is the approach advocated by the ARIA Next
Generation guidelines and the EUFOREA AR Pocket
Guide21,23. In the current survey participants told us that
insufficient nasal symptom relief, lack of effect, failure to tar-
get ocular symptoms and slow onset of action of previous
therapies, were the main reasons they started to use MP-
AzeFlu. Knowledge of how previous therapies have not met
patients’ expectations should enable physicians and pharma-
cists to select a treatment that will. Reasons for continued
use are arguably just as important to know, as these may
drive improved concordance with treatement regimens.
Superior nasal and ocular symptom relief provided by MP-
AzeFlu and a faster onset of action compared to other AR
treatments were the most commonly reported reasons for its
continued use. These perceived benefits of MP-AzeFlu were
associated with an improvement in patient QoL, a reduction
in the number of HCP visits, absenteeism and presenteeism,
and a reduction in the use of AR polypharmacy. This reduc-
tion in HCRU is important when one considers that indirect
costs, like presenteeism, account for 70% of the total cost of
AR13. Evidence from RCTs, observational studies, and cham-
ber studies back up these patient-reported outcomes31,41,42.
In these studies, MP-AzeFlu improved patient QoL, provided
twice the nasal and ocular symptom relief as an INS or an
intranasal anti-histamine, rapid and sustained AR control in
real-life and had an onset of action of 5min31,41,42.
Patient satisfaction with MP-AzeFlu was high, with mean
TSQM-9 global, effectiveness and convenience scores of 70.0,
68.3 and 72.7, respectively. TSQM-9 scores were not statistic-
ally significantly different for those on MP-AzeFlu alone
(n¼ 708) compared to the relatively small number on MP-
AzeFlu plus another AR treatment (n¼ 296). This finding may
simply be a consequence of unbalanced numbers between
groups. However, TSQM-9 global, effectiveness and conveni-
ence scores were significantly higher for those participants
with AR alone compared to those with both AR and asthma.
This may have been due worse AR control in the co-morbid
group, a confirmation of the one airway one disease concept.
Future work to investigate AR treatment satisfaction in AR
and asthma co-morbid patients stratified according to
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asthma control, asthma treatment and adherence is war-
ranted to further explore this issue.
MP-AzeFlu TSQM-9 scores appear to be higher or similar
to those reported for other AR treatments using the same
satisfaction questionnaire43–45. Comparative TSQM-9 scores
for BDP (6months treatment in PAR patients) were 70.5 for
global, 71.6 for effectiveness and 80.6 for convenience45.
Another small study of sub-cutaneous immunotherapy for
HDM allergy reported TSQM-9 global, effectiveness and con-
venience scores of 58.9, 47.2 and 63.8, respectively44. Some
country variation was noted in TSQM-9 scores in the current
survey, notably Norway had the lowest global, effectiveness
and convenience scores (63.9, 63.4 and 68.0) and the UK had
the highest (72.2, 72.9 and 74.2). This may have been due to
several factors including differences in health care systems,
in survey population as well as the underlying severity of dis-
ease, its perceived impact on patients’ lives and how MP-
AzeFlu was used to treat it (Tables 1 and 3). Specifically,
compared to the UK, Norway (NO) had a younger survey
population (NO:32.6 vs UK:40.0 yrs), more students (NO:14%
vs UK:1%), more participants who reported under-dosing
with MP-AzeFlu (NO:26% vs UK:18%) and more participants
with a poor QoL when not treated (NO:21% vs UK:11%).
Norwegian participants also reported more absenteeism
(NO: 9.7 days/yr vs UK:8.3 days/yr) and more days when
productivity was affected by AR symptoms (NO:21.4 days/yr
vs UK:13.9 days/yr). Conversely, the higher TSQM-scores
recorded by UK participants (compared to those in NO) were
associated with less pharmacy visits (UK:47% vs NO:30%),
less days absent/year (UK:54% vs NO:34%) and fewer days
productivity lost (UK:62% vs NO:33%). Furthermore, both
relative and TSQM-9 assessed satisfaction was dependent on
MP-AzeFlu pattern of use and dosing frequency, with greater
satisfaction noted when MP-AzeFlu was used every day
symptoms were expected and twice a day as recommended.
These findings emphasize the importance of understanding
AR from the patient perspective, contribute to our under-
standing of factors that can influence effectiveness and
satisfaction with AR treatments in real life, and provide
an indirect link between AR treatment satisfaction
and outcomes.
Limitations of the current survey include a reliance on a
patient-reported physician/HCP diagnosis of AR, assessment
of AR severity, and use of MP-AzeFlu. This may have resulted
in the inclusion of patients without AR, those with mild AR,
and an over-estimation of MP-AzeFlu use. Additionally, the
survey did not capture information on symptom severity or
disease control and assessed MP-AzeFlu-treated patients
only. To counterbalance these limitations, it should be noted
that the survey was large, incorporating over 1000 partici-
pants from seven European countries. These participants
were recruited from a variety of sources (e.g. patient panel,
HCP referral, patient associations), and are arguably more
representative of the AR population than patients included
in RCTs38,46. Furthermore, as MP-AzeFlu is a prescription-only
treatment in each of the countries included in this survey we
may assume that it was prescribed according to its label (i.e.
for moderate severe AR). Treatment satisfaction was assessed
using the TSQM-9. This is a reliable and validated question-
naire that has been used in many therapy areas including AR
studies, to assess patients’ satisfaction with medication27,43,45.
Use of the TSQM-9 provides confidence in the results
obtained, facilitated cross-study comparison and enabled us
to attribute any differences between patient response to real
differences in perceptions of their outcomes, as opposed to
differences in methodology or biases47.
Conclusions
The impact of AR on patients’ lives remains high. Real-life
use of MP-AzeFlu reduces that impact and is associated with
a high level of effectiveness, convenience and patient satis-
faction. Our findings may be used to encourage frank and
open physician-patient communication to achieve better AR
outcomes, inform clinical trial design and used to provide a
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